Ipratropiumbromide 40 Cyclocaps Teva

Ipratropium bromide, the active ingredient in Ipratropiumbromide 40 Cyclocaps Teva, is an anticholinergic (muscarinic antagonist) presented as a 40 µg cyclocaps for inhalation use. It treats chronic obstructive pulmonary disease, asthma (as add‑on therapy) and nasal congestion by relaxing airway smooth muscle and reducing secretions.

GNH USA supplies Ipratropiumbromide 40 Cyclocaps Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide is an anticholinergic bronchodilator used in respiratory and nasal conditions.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations. - Asthma (add‑on therapy): provides additional bronchodilation when combined with other agents. - Nasal congestion: decreases nasal secretions and eases blockage. - Rhinorrhea: reduces watery nasal discharge associated with allergic or non‑allergic rhinitis.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Cough: transient irritation of the airway. - Throat irritation: mild soreness after inhalation. - Nasal irritation: burning or stinging in the nose. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Glaucoma exacerbation: increased intra‑ocular pressure. - Paradoxical bronchospasm: worsening of breathing difficulty. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Angioedema: swelling of lips, tongue or face. - Tachycardia: rapid heart rate in susceptible individuals.

Before prescribing ipratropium bromide, consider patient‑specific factors and monitor for potential complications.

- Renal impairment: dose may need adjustment in severe renal dysfunction. - Glaucoma: avoid in patients with narrow‑angle glaucoma due to anticholinergic effect. - Urinary retention: monitor patients with prostatic hypertrophy. - Pregnancy: safety category unknown; use only if benefit outweighs risk. - Elderly: increased sensitivity to anticholinergic effects; monitor closely. - Store at ambient temperature: keep capsules in the original container, protect from moisture and heat.

Ipratropium bromide can interact with other medications that affect the cholinergic system or bronchodilation.

Major Interactions (Avoid): - Other anticholinergic agents (e.g., tiotropium, atropine): additive anticholinergic burden. - Antihistamines with anticholinergic properties: increased dryness and urinary retention. - Potent CYP inhibitors: may alter metabolism of concomitant drugs.

Moderate Interactions (Monitor Closely): - Beta‑agonists (e.g., albuterol): additive bronchodilation may cause tachycardia. - Diuretics: may exacerbate dry mouth. - MAO inhibitors: monitor for hypertensive episodes.